blank
blank

ICH E22 Guideline on general considerations for patient preference studies

1:1
Open for consultation from 12 December to 12 April, this draft ICH guideline sets out how to design and submit robust patient preference studies to inform regulatory decision‑making across a medicine’s lifecycle.

This harmonised draft guideline explains how patient preference studies (PPS) can be designed, conducted, analysed and submitted to support drug development and regulatory evaluation, including benefit–risk assessment and maintenance of approvals. It clarifies that PPS generate structured insights into what matters most to patients when weighing treatment attributes such as outcomes, risks and other relevant characteristics, and provides general methodological considerations intended to improve the quality and usability of patient preference information in regulatory contexts.

Acces this publication (pdf)
Publication cover image

Year of publication

2025

Source

European Medicines Agency (EMA)

Link to cite

Acces to Link >

Author

You might also be interested in

stocksnap-people-2574170_1920

EMA launches consultation on proof-of-concept data in paediatric oncology

This initiative is also highly relevant from a rare diseases perspective, as paediatric cancers are rare conditions where small patient populations make robust non‑clinical proof‑of‑concept data essential for responsible and ethical trial initiation.
kitt_ks-lab-2107514_1920

Towards animal-free testing: virtual control groups gain regulatory acceptance

For rare diseases, where research often relies on limited animal models and small development teams, the regulatory acceptance of virtual control groups could help streamline early non‑clinical studies while maintaining a strong focus on patient safety.
P.Sudara - Undiagnosed Day 2026

In Gdańsk, Undiagnosed Day showed why diagnosis is both a scientific and a human challenge

Bringing clinicians, researchers, patient representatives and families together, the event examined how shorter diagnostic pathways depend not only on better tests, but on shared expertise, structured phenotyping and patient-centred support.
ERDERA and european genomic data infrastructure

Strategic collaboration between GDI and ERDERA

ERDERA and the European Genomic Data Infrastructure have signed a Memorandum of Understanding to strengthen collaboration on secure cross-border access to genomic, clinical and other health-related data, supporting rare disease research and the development of personalised medicine in Europe.

ERDERA's

search form